Your browser is no longer supported. Please, upgrade your browser.
NVCR [NASD]
NovoCure Limited
Index- P/E- EPS (ttm)-0.26 Insider Own1.10% Shs Outstand103.73M Perf Week0.00%
Market Cap6.98B Forward P/E- EPS next Y-0.38 Insider Trans-2.97% Shs Float89.94M Perf Month-23.32%
Income-27.00M PEG- EPS next Q-0.11 Inst Own76.20% Short Float6.45% Perf Quarter-46.01%
Sales545.80M P/S12.78 EPS this Y205.50% Inst Trans0.35% Short Ratio7.80 Perf Half Y-64.29%
Book/sh3.98 P/B16.18 EPS next Y12.20% ROA-2.50% Target Price97.67 Perf Year-60.86%
Cash/sh8.62 P/C7.47 EPS next 5Y- ROE-6.50% 52W Range60.57 - 232.76 Perf YTD-14.21%
Dividend- P/FCF65.76 EPS past 5Y15.10% ROI2.30% 52W High-71.20% Beta0.93
Dividend %- Quick Ratio8.40 Sales past 5Y71.70% Gross Margin79.20% 52W Low10.67% ATR4.90
Employees1023 Current Ratio8.60 Sales Q/Q0.70% Oper. Margin-1.60% RSI (14)41.47 Volatility7.54% 6.64%
OptionableYes Debt/Eq1.36 EPS Q/Q-248.10% Profit Margin-4.90% Rel Volume0.81 Prev Close64.41
ShortableYes LT Debt/Eq1.36 EarningsOct 28 BMO Payout- Avg Volume743.87K Price67.03
Recom3.10 SMA20-5.73% SMA50-20.14% SMA200-53.02% Volume273,386 Change4.07%
Jan-20-22Upgrade Truist Hold → Buy $125
Jan-03-22Upgrade Evercore ISI Underperform → In-line $82
Jul-01-21Downgrade Mizuho Buy → Neutral
Apr-14-21Downgrade Wedbush Neutral → Underperform $159 → $154
Jan-25-21Reiterated Piper Sandler Overweight $140 → $225
Sep-23-20Initiated Northland Capital Outperform $200
Sep-18-20Downgrade Wells Fargo Overweight → Equal Weight $116
Sep-17-20Downgrade Truist Buy → Hold $108
Jun-01-20Resumed Oppenheimer Perform
May-01-20Downgrade Oppenheimer Outperform → Perform
Apr-09-20Downgrade Evercore ISI In-line → Underperform $58
Mar-05-20Upgrade Wells Fargo Equal Weight → Overweight $85 → $90
Jan-02-20Downgrade Evercore ISI Outperform → In-line $84 → $90
Jul-29-19Upgrade SunTrust Hold → Buy
Jul-26-19Downgrade Wedbush Outperform → Neutral $57 → $80
Jul-26-19Downgrade JP Morgan Overweight → Neutral $61 → $79
Mar-20-19Initiated SunTrust Hold
Nov-02-18Downgrade Wells Fargo Outperform → Market Perform
Jul-16-18Initiated Evercore ISI Outperform $46
Apr-18-18Reiterated Mizuho Buy $28 → $32
Jan-20-22 11:43AM  
Jan-12-22 09:38AM  
Jan-10-22 04:24PM  
07:00AM  
Jan-08-22 11:00AM  
Jan-06-22 07:56AM  
Jan-04-22 08:00AM  
Dec-19-21 06:38AM  
Dec-17-21 08:38PM  
Dec-15-21 03:38PM  
Dec-07-21 04:11PM  
Dec-06-21 07:38PM  
08:11AM  
08:00AM  
Dec-03-21 08:10AM  
Dec-02-21 06:28AM  
Nov-23-21 07:30AM  
Nov-15-21 03:19PM  
07:31AM  
07:30AM  
Nov-13-21 06:04AM  
Oct-29-21 08:20AM  
Oct-28-21 05:01PM  
04:29PM  
08:55AM  
06:30AM  
06:30AM  
Oct-25-21 05:23PM  
Oct-21-21 03:03PM  
07:30AM  
Oct-17-21 06:04AM  
Oct-14-21 11:30AM  
Oct-12-21 10:00AM  
08:50AM  
Oct-11-21 05:03AM  
Oct-10-21 07:31AM  
Oct-06-21 11:16AM  
Oct-04-21 07:30AM  
07:30AM  
07:30AM  
Sep-14-21 08:34AM  
07:00AM  
Sep-09-21 11:12AM  
08:14AM  
Sep-02-21 06:00AM  
Sep-01-21 07:50AM  
Aug-13-21 07:01AM  
Aug-04-21 10:35AM  
Jul-30-21 04:22PM  
Jul-29-21 05:18PM  
03:01PM  
07:35AM  
06:00AM  
Jul-22-21 03:03PM  
Jul-21-21 05:59AM  
Jul-19-21 11:43PM  
Jul-15-21 07:30AM  
Jul-13-21 05:45AM  
Jul-08-21 07:30AM  
05:25AM  
Jul-01-21 04:21PM  
04:08PM  
03:15PM  
12:02PM  
11:21AM  
07:15AM  
Jun-30-21 07:49AM  
Jun-29-21 11:02AM  
Jun-25-21 03:44PM  
Jun-16-21 07:30AM  
Jun-14-21 08:17AM  
Jun-05-21 06:27AM  
Jun-02-21 04:43AM  
May-28-21 07:42AM  
May-25-21 07:30AM  
May-24-21 09:21AM  
May-18-21 05:29PM  
09:22AM  
07:30AM  
May-12-21 10:12AM  
May-11-21 05:55AM  
Apr-30-21 07:11AM  
Apr-29-21 04:06PM  
02:00PM  
06:00AM  
05:45AM  
Apr-28-21 08:47AM  
Apr-26-21 08:03AM  
Apr-22-21 12:33PM  
11:18AM  
08:47AM  
Apr-21-21 02:46PM  
Apr-20-21 06:30AM  
06:04AM  
Apr-16-21 08:45PM  
06:15AM  
Apr-15-21 04:35PM  
Apr-14-21 02:16PM  
09:04AM  
08:27AM  
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burke William PatrickChief Human Resources OfficerJan 03Option Exercise10.4928,604299,99651,269Jan 05 04:52 PM
Burke William PatrickChief Human Resources OfficerJan 03Sale76.003,951300,26341,036Jan 05 04:52 PM
Danziger AsafChief Executive OfficerNov 26Buy102.444,974509,53913,276Nov 29 04:48 PM
Cordova AshleyChief Financial OfficerNov 02Sale107.2820922,42141,758Nov 03 04:11 PM
Shah PriteshChief Commercial OfficerSep 03Sale138.6850169,47773,512Sep 07 04:32 PM
Leonard Frank XChief Development OfficerSep 02Sale138.2354074,64587,153Sep 07 04:39 PM
Cordova AshleyChief Financial OfficerSep 02Sale138.23828114,45641,967Sep 07 04:37 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 02Sale138.2318125,020149,899Sep 07 04:35 PM
Shah PriteshChief Commercial OfficerSep 02Sale138.2315621,56474,013Sep 07 04:32 PM
Cordova AshleyChief Financial OfficerAug 12Option Exercise28.8236,6241,055,32954,019Aug 16 04:40 PM
Cordova AshleyChief Financial OfficerAug 12Sale140.9426,6243,752,28645,993Aug 16 04:40 PM
LEUNG GABRIELDirectorAug 05Option Exercise31.451,00031,45073,859Aug 06 04:39 PM
Madden Martin J.DirectorAug 05Sale153.13345,206384Aug 06 04:44 PM
LEUNG GABRIELDirectorAug 05Sale152.501,000152,50072,859Aug 06 04:39 PM
Shah PriteshChief Commercial OfficerAug 04Sale148.712,063306,78974,169Aug 06 04:41 PM
Shah PriteshChief Commercial OfficerAug 03Sale149.431,654247,15776,232Aug 04 05:09 PM
Benaim ElyChief Medical OfficerAug 03Sale150.1146469,65128,144Aug 04 04:59 PM
Leonard Frank XChief Development OfficerAug 03Sale149.4332849,01389,158Aug 04 05:20 PM
DOYLE WILLIAM FExecutive ChairmanAug 02Sale149.38995148,631554,398Aug 04 05:01 PM
Benaim ElyChief Medical OfficerAug 02Sale149.3853680,06728,608Aug 03 05:29 PM
Leonard Frank XChief Development OfficerAug 02Sale149.38713106,50789,486Aug 04 05:20 PM
Benaim ElyChief Medical OfficerJul 30Option Exercise83.3065154,22829,795Aug 03 05:29 PM
Benaim ElyChief Medical OfficerJul 30Sale158.96651103,48329,144Aug 03 05:29 PM
LEUNG GABRIELDirectorJul 06Option Exercise31.451,00031,45073,859Jul 08 05:23 PM
LEUNG GABRIELDirectorJul 06Sale183.541,000183,54072,859Jul 08 05:23 PM
Shah PriteshChief Commercial OfficerJun 10Sale215.0023,5405,061,10077,732Jun 11 04:26 PM
LEUNG GABRIELDirectorJun 07Option Exercise31.451,00031,45073,045Jun 08 04:49 PM
LEUNG GABRIELDirectorJun 07Sale204.551,000204,55072,045Jun 08 04:49 PM
Benaim ElyChief Medical OfficerMay 27Option Exercise47.561,83387,17730,887May 28 04:36 PM
Benaim ElyChief Medical OfficerMay 27Sale200.001,833366,60029,054May 28 04:36 PM
Benaim ElyChief Medical OfficerMay 12Sale180.481,943350,67329,054May 14 04:07 PM
Benaim ElyChief Medical OfficerMay 11Sale180.122,262407,42730,997May 12 04:15 PM
Weinberg UriChief Science OfficerMay 10Option Exercise47.563,846182,91637,317May 12 04:13 PM
Benaim ElyChief Medical OfficerMay 10Option Exercise47.561,83387,17735,092May 12 04:15 PM
Weinberg UriChief Science OfficerMay 10Sale189.655,6501,071,52231,667May 12 04:13 PM
Benaim ElyChief Medical OfficerMay 10Sale189.651,833347,62833,259May 12 04:15 PM
LEUNG GABRIELDirectorMay 05Option Exercise31.451,00031,45073,045May 06 04:15 PM
Shah PriteshChief Commercial OfficerMay 05Sale199.671,290257,574101,272May 06 04:17 PM
LEUNG GABRIELDirectorMay 05Sale199.671,000199,67072,045May 06 04:15 PM
Benaim ElyChief Medical OfficerApr 13Option Exercise64.185,958382,39736,733Apr 15 05:59 PM
LEUNG GABRIELDirectorApr 13Option Exercise31.456,000188,70078,045Apr 15 06:00 PM
Benaim ElyChief Medical OfficerApr 13Sale200.005,9581,191,60033,259Apr 15 05:59 PM
DOYLE WILLIAM FExecutive ChairmanApr 13Sale199.5595,00018,957,452555,393Apr 15 06:29 PM
Danziger AsafChief Executive OfficerApr 13Sale196.3497,97319,236,3238,184Apr 15 06:01 PM
LEUNG GABRIELDirectorApr 13Sale198.846,0001,193,03572,045Apr 15 06:00 PM
DOYLE WILLIAM FExecutive ChairmanApr 01Sale134.127,9281,063,303650,393Apr 02 04:14 PM
DOYLE WILLIAM FExecutive ChairmanMar 31Option Exercise125.259,2591,159,690658,321Apr 02 04:14 PM
Shah PriteshChief Commercial OfficerMar 09Sale131.093,524461,961101,272Mar 10 04:10 PM
Shah PriteshChief Commercial OfficerMar 08Sale130.812,627343,627104,796Mar 10 04:10 PM
Cordova AshleyChief Financial OfficerMar 08Sale130.81765100,06735,893Mar 10 04:09 PM
Longsworth Todd ChristopherGeneral CounselMar 08Sale130.812,404314,45867,714Mar 10 04:08 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 08Sale130.813,004392,941153,684Mar 10 04:06 PM
Leonard Frank XChief Development OfficerMar 08Sale130.81765100,06790,045Mar 10 04:07 PM
Shah PriteshChief Commercial OfficerMar 05Option Exercise7.1513,987100,007111,973Mar 09 04:17 PM
Shah PriteshChief Commercial OfficerMar 05Sale131.534,550598,462107,423Mar 09 04:17 PM
Benaim ElyChief Medical OfficerMar 05Sale131.532,918383,80533,259Mar 09 04:16 PM
Benaim ElyChief Medical OfficerMar 04Sale137.551,888259,70236,177Mar 05 05:44 PM
Shah PriteshChief Commercial OfficerMar 04Sale137.552,658365,61997,986Mar 05 05:43 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 04Sale137.553,854530,133156,688Mar 08 04:26 PM
Longsworth Todd ChristopherGeneral CounselMar 04Sale137.553,084424,21770,118Mar 08 04:25 PM
Leonard Frank XChief Development OfficerMar 04Sale137.5556777,99390,810Mar 08 04:24 PM
Cordova AshleyChief Financial OfficerMar 04Sale137.5556777,99337,568Mar 08 04:23 PM
Benaim ElyChief Medical OfficerMar 03Option Exercise69.373,475241,06141,540Mar 05 05:44 PM
Benaim ElyChief Medical OfficerMar 03Sale150.783,475523,96038,065Mar 05 05:44 PM
Shah PriteshChief Commercial OfficerMar 03Sale150.782,174327,796100,644Mar 05 05:43 PM
Leonard Frank XChief Development OfficerMar 02Sale152.0543065,38382,668Mar 04 05:55 PM
Cordova AshleyChief Financial OfficerMar 02Sale152.0542865,07927,249Mar 04 05:52 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 02Sale152.052,392363,711148,023Mar 04 05:50 PM
Shah PriteshChief Commercial OfficerMar 02Sale152.05912138,67291,932Mar 04 05:46 PM
Longsworth Todd ChristopherGeneral CounselMar 02Sale152.052,355358,08562,860Mar 04 05:44 PM
Danziger AsafChief Executive OfficerFeb 27Option Exercise149.109,2591,380,517206,944Mar 02 04:17 PM
Longsworth Todd ChristopherGeneral CounselFeb 27Option Exercise149.105,555828,25065,215Mar 02 04:15 PM
Cordova AshleyChief Financial OfficerFeb 27Option Exercise149.101,465218,43227,677Mar 02 04:14 PM
Leonard Frank XChief Development OfficerFeb 27Option Exercise149.101,465218,43283,098Mar 02 04:12 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerFeb 27Option Exercise149.107,7151,150,306150,415Mar 02 04:11 PM
Shah PriteshChief Commercial OfficerFeb 27Option Exercise149.103,086460,12392,844Mar 02 04:18 PM
Weinberg UriChief Science OfficerFeb 22Option Exercise7.156,50046,47534,097Feb 24 04:16 PM
Weinberg UriChief Science OfficerFeb 22Sale175.506,5001,140,75027,597Feb 24 04:16 PM